Types of Peptides: Categories, Functions, and Examples

Key Takeaways

• What they are: Short chains of amino acids linked by peptide bonds, categorized by function — not all peptides work the same way or carry the same evidence standard.
• Major categories: Hormonal/metabolic, antimicrobial, neuropeptide, oncological, cosmetic, food-derived, and research/investigational — each with distinct mechanisms and regulatory status.
• Best-evidenced: Hormonal peptide drugs (insulin, GLP-1 receptor agonists, tesamorelin) have robust FDA-approved clinical evidence. Collagen peptides have meaningful human data. Most investigational compounds have preclinical data only.
• Regulatory status: As of April 2026, more than 100 peptide drug products have secured market approval across multiple therapeutic areas (Lau and Dunn catalogued more than 60 at that time; Li and colleagues 2025 document more than 100). Research-grade peptides such as BPC-157 and TB-500 were reclassified from Category 2 to restricted compounding access effective February 2026, which forecloses their routine compounding under Section 503A; any compounding access is narrow and governed by the FDA's current bulk-drug-substances framework.
• Safety framing: Evidence quality and regulatory status are the primary determinants of known safety. Unregulated sources carry purity and dosing risks absent from approved medications.

What Peptides Are

A peptide is a chain of amino acids connected by covalent peptide bonds — the same chemical linkages that form proteins — but shorter, typically defined as 2 to 50 amino acids in length, though definitions in the literature extend the upper bound to 100 amino acids depending on the discipline. The StatPearls chapter by Kaprive, published through the National Institutes of Health, defines peptides as short strings of 2 to 50 amino acids joined by covalent peptide bonds formed in condensation reactions. The word encompasses molecules ranging in size from the dipeptide aspartame (2 amino acids) to hormone-sized chains like insulin (51 amino acids) to the largest research-grade synthetic compounds approaching small-protein territory. Classifying them by function — rather than size — is a useful frame for understanding what each type does and what evidence standard applies.

Peptide bonds and amino acid structure

Each amino acid contributes one residue to the peptide chain, connected to the next by a covalent amide bond formed between the carboxyl group of one residue and the amino group of the next — a condensation reaction that releases water. The resulting chain has a free N-terminus (amino end) and a free C-terminus (carboxyl end). The sequence of amino acids along this chain — read N to C — determines the peptide's three-dimensional shape and its receptor-binding properties. Stawikowski and Fields, in their 2012 peptide-chemistry primer published in Current Protocols in Protein Science, illustrated peptide size ranges from aspartame (a 2-amino-acid dipeptide sweetener) to oxytocin (a 9-amino-acid hormone), making the definitional span concrete.

Peptides vs. proteins: where the line is

Proteins are longer amino acid chains — conventionally above 50 amino acids — that fold into complex three-dimensional structures enabling enzymatic catalysis, structural support, and transport. Peptides tend to be shorter and act as signals rather than structures. The boundary is a convention: Sanvictores and Farci, writing in the 2025 StatPearls chapter on primary protein structure, describe proteins as polypeptide chains with higher-order structure — chemically identical to peptides, simply longer. Insulin at 51 amino acids is routinely called a protein hormone, and GLP-1 at 30 amino acids is unambiguously a peptide. The functional distinction — signaling molecule versus structural component — is more relevant than the size cutoff for clinical purposes.

How Peptides Work in the Body

The mechanism varies by type, but the most common theme is receptor binding followed by intracellular signaling. A peptide's sequence determines which receptor it fits; receptor binding triggers a downstream cascade that alters cell behavior.

Cell signaling and receptor binding

Most peptide hormones and neuropeptides bind G protein-coupled receptors (GPCRs) on cell surfaces, triggering intracellular second-messenger cascades. Posner and Laporte, in their foundational 2010 review in Progress in Brain Research, reviewed peptide hormone receptor signaling through kinase cascades and transcription-factor activation. Holst's 2007 review in Physiological Reviews described GLP-1 receptor activation on pancreatic beta cells, triggering glucose-dependent insulin secretion — an illustrative example of receptor-mediated peptide signaling.

Endogenous peptides: what your body already makes

Multiple physiologically essential peptides are synthesized continuously in the human body. Rehfeld and Bardram, writing in Acta Oncologica in 1989, reviewed peptide hormone prohormone processing that releases the active peptide via enzymatic cleavage during intracellular transport — a mechanism that applies to insulin, glucagon, GLP-1, and dozens of other endogenous hormones. Forbes's 2023 review in Vitamins and Hormones characterized insulin molecular structure at atomic resolution.

How the body breaks peptides down

Peptides are metabolized by peptidases — enzymes that cleave the amide bond at specific residue positions. This rapid degradation is why most peptides cannot survive oral ingestion intact. Fetse and colleagues, in a 2023 review in Trends in Pharmacological Sciences, reviewed therapeutic peptide stabilization strategies against enzymatic degradation, including cyclization, D-amino acid substitution, and conjugation to extending agents such as fatty acids or PEG chains.

Major Categories of Peptides

Peptides are most usefully organized by function. The categories below cover the major functional classes, with representative examples and explicit evidence grading for each.

Hormonal and metabolic peptides

Peptide hormones regulate metabolism, appetite, energy balance, and endocrine function. This is the most clinically mature peptide category, anchored by insulin (first therapeutic use in 1921) and extended by the GLP-1 receptor agonist class. Lau and Dunn's 2018 review in Bioorganic and Medicinal Chemistry catalogued more than 60 approved peptide drugs, the majority in the metabolic and endocrine categories, spanning type 2 diabetes, osteoporosis, and hormone-sensitive malignancies. Liu and colleagues, writing in Frontiers in Endocrinology in 2024, reviewed GLP-1 and dual GIP/GLP-1 incretin mechanisms, establishing the mechanistic basis for both single-receptor (semaglutide) and dual-receptor (tirzepatide) agonism.

In a Phase 3b head-to-head trial published in the New England Journal of Medicine in 2025, Aronne and colleagues (N=751, 72 weeks) reported head-to-head trial results with mean body weight reductions of 20.2% with tirzepatide versus 13.7% with semaglutide over 72 weeks. A meta-analysis by Munawar and colleagues published in Cureus in 2025 pooled approximately 29,000 participants across randomized trials and pooled randomized trial data reporting consistent weight-loss differences between the two agents. Head-to-head outcomes do not translate directly to individual response, which depends on patient biology and dosing. Both the semaglutide compound page and the tirzepatide compound page cover these FDA-approved prescription medications (Wegovy, Zepbound) and their regulatory status, including the post-2024 shortage-resolution framework that limits 503A compounding of these molecules to narrow patient-specific clinical-difference circumstances (21 U.S.C. § 353a(b)(1)(D)).

Growth hormone-releasing peptides and GHRH analogues

Growth hormone-releasing peptides (GHRPs) stimulate growth hormone secretion from the pituitary by binding the ghrelin/GHS-R receptor. Ghrelin is the endogenous archetype: Broglio and colleagues, reviewing in the Israel Medical Association Journal in 2002, reviewed ghrelin's pleiotropic effects across GH release, appetite, GI function, and cardiovascular parameters. Bednarek and colleagues, in a 2000 paper in the Journal of Medicinal Chemistry, mapped ghrelin's minimal active core (4 to 5 amino acids) needed for receptor activation — a finding that enabled the design of short, potent synthetic GHRPs. GHRH analogues such as tesamorelin work through a different mechanism: they stimulate the GHRH receptor in the pituitary to drive endogenous GH release. Tesamorelin is FDA-approved for HIV-associated lipodystrophy; the tesamorelin evidence page covers the Phase 3 clinical data in detail. Several GHRH analogs and ghrelin mimetics (sermorelin, ipamorelin, CJC-1295) are not FDA-approved and have been the subject of FDA's ongoing review of peptide bulk substances for 503A compounding; their availability and compounding status is compound-specific and has evolved with FDA's Category determinations.

Antimicrobial peptides

Antimicrobial peptides (AMPs) are among the most evolutionarily ancient peptide classes, present in organisms ranging from bacteria to humans as a frontline innate immune defense. Structurally, they are typically cationic and amphipathic, disrupting pathogen membranes through electrostatic attraction and hydrophobic insertion. Huan and colleagues, in a 2020 review in Frontiers in Microbiology, reviewed AMP antimicrobial activity against bacteria (approximately 60% of known AMP targets), fungi (26%), and viruses and parasites, establishing the classification and mechanism basis for this category. Hafeez and colleagues, in a 2021 review in the International Journal of Molecular Sciences, reviewed AMP classification systems across all living kingdoms, noting current databases catalog thousands of confirmed AMPs. Islam and colleagues, writing in Pharmaceutics in 2024, reviewed AMP mechanisms and translational barriers in the context of antibiotic resistance, where AMPs are under active investigation as an alternative to conventional antibiotics. A subclass, bacteriocins — peptides produced by bacteria to inhibit competing organisms — was reviewed by Mihaylova-Garnizova and colleagues in a 2024 paper in the International Journal of Molecular Sciences, covering bacteriocin classification and multidrug-resistant pathogen applications.

Neuropeptides

Neuropeptides act in the nervous system as neurotransmitters, neuromodulators, and neurohormones, regulating processes from appetite and sleep to mood and learning. Bhat and colleagues, in a 2021 review in Frontiers in Molecular Neuroscience, reviewed neuropeptide diversity across feeding, sleep, addiction, learning, and locomotion circuits. Representative examples:

• Oxytocin (9 amino acids): Regulates maternal bonding, social trust, and parturition. Macdonald and Macdonald's 2010 systematic review in the Harvard Review of Psychiatry documented oxytocin's social effects on behavior and decision-making in controlled human studies.
• Vasopressin (9 amino acids): Controls water reabsorption and contributes to pair bonding and social behavior through separate receptor populations. Rigney and colleagues, writing in Endocrinology in 2022, reviewed oxytocin and vasopressin circuits that modulate maternal bonding and social communication via distinct brain circuits, illustrating how two near-identical peptides produce divergent effects through receptor selectivity.
• Ghrelin (28 amino acids): Drives appetite and GH release; Shintani and colleagues' 2001 paper in Diabetes demonstrated ghrelin's appetite signaling via hypothalamic NPY pathways, opposing the satiety effects of leptin.

Yeo and colleagues, writing in Biomedicines in 2022, reviewed neuropeptide neurological implications, underscoring the neuropeptide class as a major target for neurological drug development.

Anticancer peptides

Anticancer peptides (ACPs) target tumor cells through membrane disruption, induction of apoptosis, or interference with cancer cell signaling — often with selectivity for tumor cell membranes over normal cell membranes, attributable to the altered surface charge and membrane composition of malignant cells. Chiangjong and colleagues, in a 2020 review in the International Journal of Oncology, reviewed anticancer peptide mechanisms including membrane disruption, apoptosis induction, and signaling interference in preclinical models, with clinical trial progress noted for several candidates. Zhang and colleagues, writing in Biomaterial Translational Research in 2023, classified anticancer peptides and discussed their clinical development potential. Lath and colleagues, in a 2023 review in Biotechnology and Genetic Engineering Reviews, reviewed tumor selectivity mechanisms and therapeutic applications. Peptide-drug conjugates — anticancer peptides linked to cytotoxic payloads — represent an active area of development; Karami Fath and colleagues, writing in Cell and Molecular Biology Letters in 2022, reviewed tumor-targeting peptides and cell-penetrating peptides for solid tumor applications. Anticancer peptides in the membrane-disrupting, apoptosis-inducing, and peptide-drug-conjugate classes described above remain investigational; no FDA-approved drug in those specific structural classes is on the U.S. market as of April 2026. FDA-approved peptide oncology drugs (leuprolide, degarelix, octreotide, lanreotide) act via endocrine receptor pathways rather than direct tumor-cell membrane disruption.

Cell-penetrating peptides

Cell-penetrating peptides (CPPs) are typically fewer than 30 amino acids in length and are characterized by their ability to cross cell membranes through endocytosis or direct translocation. Their primary use is as drug delivery vehicles — carrying nucleic acids, proteins, or small-molecule drugs into cells that would otherwise exclude them. Derakhshankhah and Jafari, writing in Biomedicine and Pharmacotherapy in 2018, reviewed CPP mechanisms and cargo delivery applications across multiple therapeutic contexts. Nhàn and colleagues, in a 2023 review in the International Journal of Molecular Sciences, reviewed peptide-based cancer therapeutics including tumor-targeting peptides as a subclass of CPPs with selectivity for malignant tissue.

Collagen and structural peptides

Hydrolyzed collagen peptides are fragments of the collagen protein produced through enzymatic or chemical hydrolysis and are among the most widely sold dietary supplements. Evidence for oral collagen peptide supplementation in human randomized controlled trials is better developed than for most consumer peptide categories. Proksch and colleagues, in a 2014 double-blind RCT published in Skin Pharmacology and Physiology (N=69 women, 8 weeks), reported collagen hydrolysate trial outcomes showing greater skin elasticity than placebo in the trial. Seong and colleagues, in a 2024 RCT published in the Journal of Cosmetic Dermatology, reported low-molecular-weight collagen peptide outcomes with greater improvements in skin wrinkle depth, elasticity, and hydration than placebo in the trial. The distinction between supplemental collagen peptides and whole-food collagen sources shapes how bone broth and collagen peptides perform differently in practical nutritional use.

Cosmetic peptides

Cosmetic peptides are topical ingredients used in skincare formulations. Pintea and colleagues, in a 2025 review in Biomolecules, classified cosmetic peptide functional types into four categories: signal peptides (proposed to stimulate collagen or elastin synthesis), carrier peptides (deliver trace minerals), neurotransmitter-inhibitor peptides (proposed to reduce expression-line depth by modulating muscle contraction), and enzyme-inhibitor peptides (proposed to slow collagen breakdown). Sionkowska and colleagues, in a 2020 review in Materials, reviewed collagen peptides in cosmetic applications with a focus on formulation science. Cosmetic peptides are regulated as cosmetics under the FD&C Act § 201(i) and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Products making structure-or-function claims beyond appearance modification may be regulated as drugs under § 201(g); such claims require drug-approval pathways, not cosmetic regulatory status.

Food-derived (bioactive) peptides

Bioactive peptides are released from dietary proteins during digestion, fermentation, or enzymatic processing. They include ACE-inhibitory peptides from dairy and fish (with proposed antihypertensive effects), antioxidant peptides from legumes and grains, and antimicrobial peptides released from food proteins in the gut. Zaky and colleagues, in a 2022 review in Frontiers in Nutrition, reviewed food-derived bioactive peptides from plant, animal, marine, and dairy sources with antioxidative, anti-inflammatory, and antimicrobial properties. Peighambardoust and colleagues, in a 2021 review in Biomolecules, reviewed functional-food bioactive peptides with antihypertensive, antioxidant, and antimicrobial properties. Grootaert and colleagues, writing in Food and Function in 2017, reviewed ACE-inhibitory egg peptides for cardiovascular support as representative food-derived antihypertensives. Kim and Wijesekara, in a 2012 review in Advances in Food and Nutrition Research, reviewed marine fish peptides as antihypertensive functional food ingredients.

Research and investigational peptides

A large category of synthetic peptides has been studied in laboratory or animal models but is not FDA-approved for human use. Examples include:

• BPC-157: A 15-amino-acid gastric-derived peptide investigated for tissue-healing effects in rodent models. Gwyer and colleagues, in a 2019 review in Cell and Tissue Research, reviewed BPC-157 preclinical mechanisms in tendon, ligament, and muscle healing. Józwiak and colleagues, in a comprehensive 2025 review in Pharmaceuticals (Basel), reviewed BPC-157 FDA status and the insufficiency of human evidence. As of April 2026, BPC-157 was reclassified from Category 2 to restricted compounding access effective February 2026, which forecloses routine 503A compounding. Any compounding access is narrow and governed by the FDA's current bulk-drug-substances framework.
• Thymosin beta-4 (TB-500): An endogenous actin-binding peptide studied for wound healing. Malinda and colleagues, in a 1999 study in the Journal of Investigative Dermatology, reported thymosin beta-4 wound model data in which thymosin beta-4 accelerated re-epithelialization by 42% at day 4 and up to 61% at day 7 in a rat full-thickness wound model. Human trial data is limited. As of April 2026, TB-500 was reclassified from Category 2 to restricted compounding access effective February 2026, which forecloses routine 503A compounding. Any compounding access is narrow and governed by the FDA's current bulk-drug-substances framework.
• MOTS-c: A 16-amino-acid mitochondria-derived peptide under early investigation for metabolic effects in preclinical models. No completed Phase 3 human trials exist as of April 2026.

Hilchie and colleagues, reviewing in Advances in Experimental Medicine and Biology in 2019, reviewed cationic amphipathic peptide delivery strategies, highlighting that preclinical promise requires rigorous translational work to become clinical utility. This category carries the highest uncertainty for both efficacy and safety in humans. Many research-grade compounds in this group are marketed outside the regulated prescription-drug framework, often labeled for research use only. Products sold this way fall outside pharmaceutical-grade manufacturing controls and outside the dietary supplement framework under DSHEA (21 U.S.C. § 321(ff)); synthetic research peptides like BPC-157 do not meet the statutory definition of a dietary ingredient and cannot be lawfully marketed as dietary supplements.

FDA-Approved Peptide Drugs: What Approval Means

FDA approval requires completion of Phase 1 through Phase 3 clinical trials demonstrating safety and efficacy in the target population, pharmaceutical-grade manufacturing, and accurate labeling. Zhang and colleagues, in their 2020 review in the International Journal of Pharmaceutics, analyzed approved peptide therapeutics, cataloging dosage forms and delivery routes for the FDA-approved subset. As of April 2026, Li and colleagues noted in their 2025 Amino Acids review that documented continued expansion of the approved peptide drug landscape, with the FDA-approved subset spanning multiple disease areas. Selected approved compounds by category:

• Metabolic/hormonal: Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), insulin (multiple forms), tesamorelin (Egrifta), teriparatide (Forteo), abaloparatide (Tymlos)
• Oncology/endocrine: Leuprolide (Lupron), degarelix (Firmagon), octreotide (Sandostatin), lanreotide (Somatuline)
• Cardiovascular: Eptifibatide (Integrilin), nesiritide (Natrecor)
• Infectious disease / diagnostic: Enfuvirtide (Fuzeon, HIV entry inhibitor), cosyntropin (Cortrosyn, adrenal function testing)

What "Safe" Means for Peptides — and What It Depends On

Safety is category-dependent and evidence-dependent. The same principle applies across all peptide types: the risk profile is only as well-characterized as the clinical data available for that specific compound.

FDA-approved peptides: known profiles from clinical trials

Approved peptide medications have defined safety profiles because Phase 1 through Phase 3 trials in thousands of participants established them. Chandarana and colleagues, in a 2024 review in Current Drug Research Reviews, reviewed peptide therapeutic specificity and low systemic toxicity compared to small-molecule drugs — a reflection of receptor-targeted pharmacology. For GLP-1 receptor agonists, the documented adverse effect profile (gastrointestinal: nausea, vomiting, constipation) is attributable to the mechanism of action and is labeled and monitored. For growth hormone-releasing peptides such as tesamorelin, the Phase 3 program established the safety and efficacy profile that supported FDA approval.

Unregulated research peptides: evidence gaps and sourcing risks

Research-grade peptides sold through unregulated channels carry manufacturing risks that pharmaceutical-grade products do not. D'Hondt and colleagues, writing in Journal of Pharmaceutical and Biomedical Analysis in 2014, documented peptide medicine impurities as a quality-control problem absent from pharmaceutical-grade synthesis pipelines. Beyond contamination risk, the absence of human trial data means that adverse effects in individuals cannot be predicted from the preclinical literature. Bays and colleagues, writing in a 2024 review in Obesity Pillars, reviewed compounded peptides in obesity medicine — noting that clinician and patient confusion about unregulated products creates genuine safety risks.

What affects safety at the individual level

Regulatory status and manufacturing quality are the primary determinants of known safety for any peptide. Beyond those factors, delivery route (oral versus injectable) and individual biology (organ function, existing conditions, concurrent medications) determine how a compound is absorbed, distributed, and cleared. Whether baseline biomarkers were assessed before use determines whether subsequent biological changes can be detected and contextualized.

Which Biomarkers Are Relevant to Peptide Science?

The peptide categories described above each connect to measurable bloodwork markers. Understanding baseline values in these markers creates the objective reference framework for evaluating any response to a peptide intervention.

• Fasting insulin and glucose: Core markers for metabolic and hormonal peptide effects. Fasting insulin and glucose characterize insulin sensitivity and pancreatic function at baseline.
• HbA1c: The 3-month average blood glucose endpoint central to metabolic peptide clinical trials. A baseline HbA1c is prerequisite for interpreting any glycemic change.
• IGF-1: The primary downstream marker for growth hormone axis peptides. IGF-1 reflects integrated GH secretion over days, making it the most clinically useful GH-axis marker for baseline assessment.
• hs-CRP: Systemic inflammatory marker relevant for antimicrobial and tissue-repair peptide categories. High-sensitivity CRP provides a reference point for tracking inflammatory burden.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): Relevant for metabolic peptide monitoring. A baseline triglycerides and lipid panel is standard before GLP-1 class interventions, given documented effects on lipid parameters.
• Kidney function (eGFR, creatinine): Renal clearance affects injectable peptide pharmacokinetics. An eGFR baseline is required before many approved injectable peptide protocols.
• Liver enzymes (ALT, AST): Standard hepatic function baseline for any compound with hepatic metabolism. ALT is a sensitive early marker of hepatocellular stress.

Running a metabolic health biomarker test before exploring any peptide protocol — dietary, pharmaceutical, or investigational — establishes the objective reference points that make any subsequent biological change interpretable.

When These Questions Deserve Professional Attention

If the experience driving interest in any peptide category is a symptom — metabolic dysfunction, hormonal irregularities, inflammatory conditions, weight dysregulation, or poor recovery — that experience deserves clinical evaluation before any compound is considered. The taxonomy covered here is a framework for understanding evidence quality; it is not a guide to self-treatment. A primary care evaluation and objective bloodwork are the appropriate starting points.

The principle underlying that approach — understanding the biology before acting on it — is foundational to Superpower's approach to preventive health. In a category where evidence quality ranges from decades of large randomized controlled trials (GLP-1 agonists) to small preclinical studies for most investigational compounds, objective baselines are the most durable foundation for any clinical decision.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a broad category, including both FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile. Superpower Health does not prescribe, sell, or facilitate access to peptide compounds that are not FDA-approved for any indication in the United States.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Non-approved research peptides, often sold labeled "for research use only," are not regulated for human safety, efficacy, or manufacturing quality. Products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

This content is not a substitute for medical advice, diagnosis, or treatment. If you are considering any peptide-based compound, consult a licensed healthcare provider before proceeding. Individual health conditions, medications, and organ function affect both suitability and response.

For information about FDA-approved peptide medications, visit dailymed.nlm.nih.gov. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.